Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03515759
Other study ID # 2062010
Secondary ID
Status Completed
Phase
First received
Last updated
Start date November 1, 2017
Est. completion date January 15, 2019

Study information

Verified date April 2018
Source Cairo University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

60 pregnant women with singleton living fetus between 34 -38 wks gestation known to have severe hypertension in the current pregnancy were included.

All participants underwent Doppler ultrasonography to evaluate the Feto-Placental Circulation within 24 hours from Pregnancy Termination.

Flow Velocity Waveforms were obtained from: Umbilical Artery (UA), Middle Cerebral Artery (MCA), Ductus Venosus (DV), Umbilical Vein (UV).

From the flow velocity waveforms the following indices were measured:

UA & MCA: Pulsatility Index (PI) & Resistance Index (RI), DV: Peak Velocity Index For veins (PVIV), Peak Systolic Velocity (PSV) & a- wave.

UV Flow: Presence or Absence of Pulsatile Flow.


Description:

60 pregnant women (aged from 18- 35 years) with singleton healthy living fetus between 34 -38 wks gestation known to have severe hypertension in the current pregnancy were included.

Chronic Hypertension was defined as a blood pressure value of 140/90 mm Hg or higher diagnosed before 20 weeks' gestation or preconception. Gestational Hypertension was defined as blood pressure value of 140/90 mm Hg or higher on 2 occasions at least 4 hours apart that occurred after 20 weeks' gestation in a patient with previously normal blood pressure. Preeclampsia was defined as blood pressure value of 140/90 mm Hg or higher on 2 occasions at least 4 hours apart and proteinuria (Proteinuria is defined as the excretion of 300mg or more of protein in a 24 hour urine collection or 1+ by The dipstick method) that occurred after 20 weeks' gestation in a patient with previously normal blood pressure. Chronic hypertension & gestational hypertension was considered to be severe if systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥110 mmHg, or both & persists for 15 minutes or more. Preeclampsia was considered to be severe in the following conditions: Blood pressure of 160/110 or more, Thrombocytopenia (platelet count less than 1000,000 / microliter), impaired liver function (elevated blood levels of liver transaminases to twice the normal concentration) , severe persistent right upper quadrant or epigastric pain unresponsive to medication and not accounted for by alternative diagnosis, or both, the new development of renal insufficiency (elevated serum creatinine > 1.1mg/dL or a doubling of serum creatinine in the absence of other renal disease) & new-onset cerebral or visual disturbances. Patients with other maternal medical disorders rather than hypertension or experienced rupture of membrane or antepartum hemorrhage (placenta previa or accidental hemorrhage) were excluded. Also, patients who received respiratory depressants medications within 2 hours from the delivery of the fetus (e. g., opioid analgesic) were excluded.

Informed consents were obtained from all participants after explanation of the study and its aims. All participants underwent the following: Full history taking including a detailed history of the hypertension state during the current pregnancy (onset, course, current medication, and whether the blood pressure is controlled or not). complete physical examination: general (including BMI & blood pressure measurement) and obstetric examinations. Routine obstetric ultrasound: to confirm gestational age & fetal viability & number, assess fetal weight (EFW) and growth percentile & amniotic fluid index (AFI) & to exclude fetal anomalies. Laboratory investigations (Complete blood count (CBC) - Urine analysis for albuminuria - Liver enzymes & kidney function). In addition to Doppler ultrasonography assessment using GE Voluson Pro-V and GE Voluson E10 with 3.5-5 MHz abdominal transducer). The color flow imaging (to identify the vessels) & pulsed wave velocimetry was used to obtain flow velocity waveforms within 24 hours of pregnancy termination from: Umbilical artery (UA): from a free-floating loop in the mid portion of the cord, Middle cerebral artery (MCA): obtained from a transverse image of the fetal head at the level of sphenoid bones (color flow im¬aging was used to display the circle of Willis), Ductus venosus (DV) was sampled soon after its origin from the umbilical vein & finally Umbilical vein flow (UV) assessment. In all Doppler studies, while the woman is lying in a semi-recumbent position, the angle of insonation of the vessels is < 45 degrees & the high-pass filter is set at 100 Hz. Care is taken not to exert undue pressure on the fetal head because this alters the flow velocity waveforms from the MCA. Furthermore, examination of the fetal vessels was performed in the absence of fetal body and respiratory movements, with a fetal heart rate ranging from 120-160 bpm. Measurements was obtained from ≥ 4 consecutive flow velocity waveforms of good quality and averaged. From the flow velocity waveforms of the UA & MCA, the pulsatility index (PI) & the resistance index (RI) was measured. From the flow velocity waveforms of the DV, peak velocity index (PVIV), peak systolic velocity (PSV) and A wave was measured. From the umbilical vein flow, the presence or absence of pulsatile flow was recorded. All labours was attended by an expert neonatologist who was blinded to the results of Doppler indices measurements & the following was recorded: APGAR score at (1 & 5 min) - Neonatal birth weight (Fetal growth restriction will defined as birth weight of less than 10th percentile of newborn weight in normal pregnancies at corresponding gestational age) - the occurrence of respiratory complications [Transient Tachypnea of the newborn (TTN) or Respiratory Distress Syndrome (RDS)] - The further need for neonatal intensive care unit (NICU) admission & Perinatal death.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date January 15, 2019
Est. primary completion date January 15, 2019
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 35 Years
Eligibility Inclusion Criteria:

- Gestational age (GA): 34 - 38weeks of gestations (confirmed by a reliable date for the last menstrual period or /and 1st trimester ultrasound scan).

- The current Pregnancy complicated with severe hypertension (gestational hypertension, preeclampsia, chronic hypertension and chronic hypertension with superimposed preeclampsia).

- Singleton living fetus.

Exclusion Criteria:

- Maternal medical disorders rather than hypertension.

- Fetal congenital anomalies.

- Rupture of membrane.

- Antepartum hemorrhage (placenta previa or accidental hemorrhage).

- The maternal administration of respiratory depressants within 2 hours from the delivery of the fetus (e. g., opioid analgesic )

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Egypt Kasr Elainy Hospital (Faculty of Medicine - Cairo University) Cairo

Sponsors (1)

Lead Sponsor Collaborator
Cairo University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary The diagnostic value of umbilical artery (UA) Doppler indices (RI & PI) in predicting adverse perinatal outcome among severely hypertensive patients sensitivity and specificity of umbilical artery RI & PI in detecting IUGR and APGAR score less than 7 at 5 minutes within 24 hours before delivery and post natal
Secondary The diagnostic value of Middle cerebral artery (MCA) Doppler indices (RI & PI) in predicting adverse perinatal outcome among severely hypertensive patients sensitivity and specificity of middle cerebral artery RI & PI in detecting IUGR and APGAR score less than 7 at 5 minutes within 24 hours before delivery and post natal
Secondary The diagnostic value of cerebro/placentaI Ratio in predicting adverse perinatal outcome among severely hypertensive patients. sensitivity and specificity of of MCA/UA PI Ratio in detecting IUGR and APGAR score less than 7 at 5 minutes within 24 hours before delivery and post natal
Secondary The diagnostic value of Ductus Venousus Doppler indices in predicting adverse perinatal outcome among severely hypertensive patients. sensitivity and specificity of peak velocity index (PVIV), peak systolic velocity (PSV) and abnormal A wave in detecting IUGR and APGAR score less than 7 at 5 minutes within 24 hours before delivery and post natal
See also
  Status Clinical Trial Phase
Recruiting NCT03299777 - Correlation Between Changes in Liver Stiffness and Preeclampsia as Shown by Fibroscan N/A
Completed NCT03650790 - C1q/TNF-related Protein 9 (CTRP 9) Level in Preeclamptic Obese and Non-obese Pregnancies N/A
Recruiting NCT03605511 - TTP and aHUS in Complicated Pregnancies
Not yet recruiting NCT03302260 - Identifying Methods for Postpartum Reduction of Vascular Events: Pilot Randomized Controlled Trial N/A
Completed NCT02911701 - Effect of Acetaminophen on Postpartum Blood Pressure Control in Preeclampsia With Severe Features Phase 4
Completed NCT01911494 - Community Level Interventions for Pre-eclampsia N/A
Terminated NCT02025426 - Phenylephrine Versus Ephedrine in Pre-eclampsia Phase 4
Completed NCT01352234 - Comparison of Doses of Acetylsalicylic Acid in Women With Previous History of Preeclampsia Phase 4
Active, not recruiting NCT02031393 - Establishing First Trimester Markers for the Identification of High Risk Twin N/A
Terminated NCT00141310 - Sildenafil Citrate for the Treatment of Established Pre-Eclampsia Phase 2
Completed NCT00157521 - L-Arginine in Pre-Eclampsia Phase 3
Completed NCT04795154 - Prenatal Yoga as Complementary Therapy of Preeclampsia N/A
Completed NCT00004399 - Randomized Study of Nimodipine Versus Magnesium Sulfate in the Prevention of Eclamptic Seizures in Patients With Severe Preeclampsia N/A
Completed NCT00005207 - Renin and Prorenin in Pregnancy N/A
Recruiting NCT04551807 - Natural Versus Programmed Frozen Embryo Transfer (NatPro) Phase 3
Terminated NCT04092829 - Impact of Corpus Luteum Presence or Absence in the Incidence of Preeclampsia After Frozen Embryo Transfer N/A
Recruiting NCT06067906 - Weight Loss Following an Episode of Pre-eclampsia Using a Dissociated or Hypocaloric Diet in Overweight or Obese Patients N/A
Recruiting NCT06317467 - Role of Anti-C1q Autoantibodies in Pregnancy
Completed NCT02218931 - ESTEEM - Effect of Simple, Targeted Diet in Pregnant Women With Metabolic Risk Factors on Pregnancy Outcomes N/A
Active, not recruiting NCT04484766 - Preeclampsia Associated Vascular Aging